Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIANT: Dulaglutide in Severe Intracranial Atherosclerotic Disease
NCT07282041Phase 3Recruiting
- Sponsor
- National University of Singapore
- Start
- Dec 2025
- Primary completion
- Dec 2030
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of dulaglutide in intracranial atherosclerosis (ICAD), ischemic stroke, sponsored by National University of Singapore. Started Dec 2025; status: recruiting.
02
Drugs
dulaglutide
03
Conditions
intracranial atherosclerosis (ICAD)ischemic stroke
Beyond the preview
Go deeper on NCT07282041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07282041.